期刊文献+

223例新诊断多发性骨髓瘤临床特点及疗效分析 被引量:21

The clinical features, chemotherapy responses and survival of 223 patients with newly diagnosed multiple myeloma
原文传递
导出
摘要 目的探讨我国各型多发性骨髓瘤(MM)所占比例、临床与实验室检查特点、对化疗的反应及长期生存情况。方法回顾性分析我院2000年1月至2007年9月收治的223例新诊断的各型MM的临床资料。结果IgG、IgA、轻链型、IgD、IgM和双克隆型MM分别占48.0%、20.6%、25.6%、4.0%、0.9%和0.9%,未见IgE型和不分泌型MM。中位发病年龄58岁,IgA型患者年龄最大,轻链型最小(P=0.004)。初诊时最常见的临床表现为贫血、骨痛和肾功能损害,分别占67.7%、61.0%和45.3%。轻链型与IgG和IgA型相比,肾功能损害明显,病理性骨折与高钙血症发生率高,血清蛋白电泳不出现单克隆球蛋白峰,总球蛋白多不升高。IgD型临床表现与轻链型相似。在≥4疗程的89例患者中,化疗总有效率61.8%,各型MM之间差异无统计学意义(P=0.595)。结论各型MM中,以IgG型最常见,贫血、骨痛和肾功能损害是MM患者初诊时最常见的症状。应常规行免疫固定电泳以避免漏诊轻链和IgD型多发性骨髓瘤。 Objective To explore the proportion, clinical and laboratory features, chemotherapy responses and long term survival of different kinds of newly diagnosed multiple myeloma (MM) in China. Methods The clinical data of 223 cases of newly diagnosed MM patients were gathered in the First Affiliated Hospital of Sun Yat-sen University from Jan, 2000 to Seb, 2007 were retrospectivley analyzed. Results The proportions of each kind of MM including IgG, IgA, light chain, IgD, IgM and biclonal MM were 48. 0% ,20. 6% ,25.6% ,4.0% ,0.9% and 0.9% respectively. No IgE and nonsecretary myeloma was found. The median age of onset was 58 years, of which that of the IgA type was the oldest one and the light chain type was the youngest (P =0. 004). Bone pain, renal insufficiency, and anemia were the most common symptoms which accounted for 67.7% ,61.0% and 45. 3% respectively. The incidences of renal inadequacy, hypercalcemia and pathological fracture in light chain type were higher than those in IgG and IgA types. Besides, no M protein were found in serum protein electrophoresis and no elevation of total globulin. The cinical features of IgD type were similar to that of the light-chain type. The total chemotherapy efficacy rate of 89 patients who were treated with more than 3 cycles in our hospital is 61.8% , which has no difference in all types. Median overall survival of the 89 patients was 33.0 months. Conclusion IgG is the most common type in MM. Bone pain, anemia, hypercalcemia and renal insufficiency are common symptoms. Immunofixation electrophoresis should be performed routinely to avoid missed diagnosis of lightchain and IgD types of MM.
出处 《中华医学杂志》 CAS CSCD 北大核心 2008年第30期2140-2143,共4页 National Medical Journal of China
关键词 多发性骨髓瘤 药物疗法 无病生存 Multiple myeloma Drug therapy Disease-free survival
  • 相关文献

参考文献8

  • 1麦玉洁,邱录贵,李睿,靳风艳,白洁,万长春,王建祥,季林祥,肖志坚,钱林生.432例多发性骨髓瘤临床分析[J].白血病.淋巴瘤,2004,13(4):198-201. 被引量:27
  • 2庄俊玲,武永吉,钟玉萍,何坚,沈悌,张之南.多发性骨髓瘤218例临床分析[J].中国实用内科杂志,2004,24(2):108-110. 被引量:61
  • 3武永吉.多发性骨髓瘤//张之南,沈悌,血液病诊断及疗效标准,3版.北京:科学出版社,2007:232-235.
  • 4Blade J, SamsonD, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and hemopoietic stem cell transplantation. Myeloma Subcommittee of the EMBT. european group for blood and marrow transplant. Br J Haematol, 1998,102 : 1115-1123.
  • 5Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc, 2003, 78:21-33.
  • 6陶中飞,傅卫军,陈玉宝,袁振刚,王东星,侯健.206例多发性骨髓瘤预后因素分析及分期评价[J].癌症,2006,25(4):461-464. 被引量:44
  • 7Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: Presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol, 1994, 12:2398-2404.
  • 8Shimamoto Y, Anami Y, Yamaguchi M. A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients. Eur J Haematol, 1991,47:262-267.

二级参考文献18

  • 1李守静,李宏然,赵相印,李清朗.多发性骨髓瘤诊断的探讨(附2547例分析)[J].中华肿瘤杂志,1995,17(1):43-46. 被引量:151
  • 2武永吉 张安.骨髓瘤前期2例[J].中华内科杂志,1992,31:545-546.
  • 3Greipp R P, Leong T, Bennett J, et al. Plasmablastic morphology-an independent prognostic factor with clinical and laboratory correlates:Eastern Cooperative Oncology Group (ECOG)Myeloma Trial E9486 Report by the ECOG Myeloma Laboratory Group[J]. Blood,199
  • 4Zojer N, Konigsberg R, Ackermann J, et al. Deletinn of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detectinn by interphase fluorescence in situ hubridization[J]. Blood,2000,95(6)1925-1930.
  • 5Fonseca R, Harrington D ,Oken M, et al. Biologic al and prognostic significance of interphase fluorescence in situ hubridization detection of chromosome 13 abnormalities (△ 13)in multiple myeloma:an Eastern Cooperative Oncology Group Study[J]. Cancer Rea
  • 6Robert K, Morie G, Thomas W, et al. Review of 1027 patients with newly diagnosed multiple myeloma[J]. Mayo Clin Proc, 2003,78:21 -33.
  • 7Knudsen L M, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis[J]. Eur J Haematol,2000,65:175-181.
  • 8Shaheen H, Ghanghroo Ⅰ, Malik Ⅰ. Clinicopathological features and management of Pakistani patients with multiple myeloma[J]. J Pak Med Assoc, 1999, 49(10):233-237.
  • 9Myeloma Trialists' Collaborative Group.Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma:an overview of 6,633 patients from 27randomized trials[J].J Clin Oncol,1998,16(12):3832-3842.
  • 10Clerc D,Fermand J P,Mariette X.Treatment of multiple myeloma[J].Joint Bone Spine,2003,70(3):175-186.

共引文献125

同被引文献165

引证文献21

二级引证文献171

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部